Xbiotech announces oral presentation of atopic dermatitis results for bermekimab at 2019 eadv congress in madrid, spain

Xbiotech announced that dr. alice gottlieb will be presenting clinical findings for bermekimab in the treatment of atopic dermatitis (ad) at the european academy of dermatology and venereology (eadv) congress being held in madrid spainoctober 9-13th. dr. gottlieb will present data from a multicenter, phase 2 study in which bermekimab monotherapy showed rapid and dose dependent improvement in ad. a highlight of the data to be reported is the observation that after only 8 weeks of bermekimab therapy, three-fourths of patients achieved 75% improvement in their eczema area and severity index (easi 75) scores, a key measure of disease severity in ad. the current standard of care and the only approved biological therapy for ad involves a 16 week treatment regimen, which clinical trials have shown to result in 44-51% of patients achieving 75% improvement in easi score. another key finding to be reported in the bermekimab study was a dramatic reduction in itch, which can be debilitating in eczema patients.
XBIT Ratings Summary
XBIT Quant Ranking